Endpoints: His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor Read More
Exceptionally high-affinity Ras binders that remodel its effector domainJournal of Biological Chemistry Read More
An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of PeptidesJournal of the American Chemical Society Read More